Sarepta Therapeutics Inc. (SRPT) PT Raised to $76.00 at Oppenheimer Holdings Inc.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) had its target price boosted by analysts at Oppenheimer Holdings Inc. from $60.00 to $76.00 in a report issued on Monday. Oppenheimer Holdings Inc.’s target price suggests a potential upside of 36.37% from the stock’s current price.
A number of other equities research analysts have also commented on the stock. Cowen and Company reissued a “market perform” rating on shares of Sarepta Therapeutics in a report on Monday, August 15th. Janney Montgomery Scott raised shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $30.00 to $65.00 in a report on Monday. Jefferies Group reissued an “underperform” rating and set a $7.00 price objective on shares of Sarepta Therapeutics in a report on Saturday, June 25th. Robert W. Baird reissued an “outperform” rating and set a $23.00 price objective on shares of Sarepta Therapeutics in a report on Monday, July 18th. Finally, JMP Securities reissued an “underperform” rating and set a $10.00 price objective on shares of Sarepta Therapeutics in a report on Sunday, July 24th. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $51.01.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Monday. The stock has a 50 day moving average of $28.17 and a 200 day moving average of $21.37. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $56.80. The stock’s market capitalization is $2.67 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period in the previous year, the company earned ($0.87) EPS. On average, equities research analysts forecast that Sarepta Therapeutics will post ($4.98) EPS for the current year.
In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the sale, the chief executive officer now directly owns 76,983 shares in the company, valued at approximately $2,309,490. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.90% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the company. Teacher Retirement System of Texas increased its stake in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $154,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $211,000. National Planning Corp increased its stake in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the period. Finally, First Allied Advisory Services Inc. increased its stake in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the period. Hedge funds and other institutional investors own 72.09% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.